
Radiopharm Theranostics and BAMF Health Announce Strategic Collaboration to Manufacture and Dose 18F-RAD 101 for Phase 2b Imaging Study of Brain Metastasis
BAMF Health will be a site for Radiopharma Theranostics’ clinical trial and will also be manufacturing 18F-RAD 101 for other trial sites.
October 21, 2024